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Abstract—During metastasis, circulating tumor cells migrate
away from a primary tumor via the blood circulation to form
secondary tumors in distant organs. Mounting evidence from
clinical observations indicates that the number of circulating
tumor cells (CTCs) in the blood correlates with the progres-
sion of solid tumors before and during chemotherapy.
Beyond the well-established role of CTCs as a ﬂuid biopsy,
however, the ﬁeld of targeting CTCs for the prevention or
reduction of metastases has just emerged. Conventional
cancer therapeutics have a relatively short circulation time in
the blood which may render the killing of CTCs inefﬁcient
due to reduced exposure of CTCs to drugs. Nevertheless,
over the past few decades, the development of nanoparticles
and nanoformulations to improve the half-life and release
proﬁle of drugs in circulation has rejuvenated certain
traditional medicines in the emerging ﬁeld of CTC neutral-
ization. This review focuses on how the principles of
nanomedicine may be applied to target CTCs. Moreover,
inspired by the interactions between CTCs and host cells in
the blood circulation, novel biomimetic approaches for
targeted drug delivery are presented.
Keywords—Circulating tumor cells, Metastasis, Nanomedi-
cine.
INTRODUCTION
Metastasis contributes to more than 90% of cancer-
associated mortality.92 It is generally hypothesized that
primary tumors shed circulating tumor cells (CTCs) via
the lymphatics to neighboring lymph nodes or through
hematogenous dissemination to distant organs. The
presence of CTCs in the blood represents a poor prog-
nosis in a variety of carcinomas.21,84,140 Nevertheless,
the effective treatment for this deadly disease remains
clinically challenging. In the case of hematogenous
metastasis, CTCs must complete several sequential
steps: (1) detachment from the primary tumor, (2) in-
travasation into the vascular system, (3) survival in the
blood circulation, and (4) extravasation into the target
tissue.41 The ﬁnding that very few metastases develop
despite the release of millions of CTCs into the vascu-
lature daily by large primary tumors suggests that the
process of metastasis is very inefﬁcient.76 This is con-
sistent with a recent experimental demonstration that
only a small subpopulation of metastasis-initiating cells
(MICs) among human luminal breast cancer CTCs gave
rise to distant metastases in mice and the existence of
MICs correlated with overall metastatic incidence in
patients.11 Therefore, early metastasis intervention
procedures, such as neutralization of CTCs and par-
ticularlyMICs in circulation, may offer new therapeutic
opportunities.
The majority of existing cancer therapies including
nanomedicine- and nanoformulation-based therapeu-
tics target solid tumors (primary and metastatic).23 The
underlying principle of most current nanotechnology-
based drug delivery platforms is based on the observa-
tion that tumor-associated vasculatures are more leaky
than normal vessels and thus are more permeable to
nanoparticles and macromolecules. Additionally, solid
tumors retain large molecules due to inefﬁcient lym-
phatic drainage.16,27 While the enhanced permeability
and retention (EPR) effect has proven to be a key
pharmacokinetic feature for existing nanomedicines,
this mechanism is not applicable to potential
nanomedicines that target CTCs in circulation. The
physical and biological environments surrounding
CTCs are drastically different from those of solid tu-
mors. CTCs are exposed to a broad range of ﬂuid shear
stresses when transiting in different vascular compart-
ments (arteries, veins, and capillaries). Compared to
non-transformed epithelial cells, transformed cells are
remarkably resistant to varied ﬂuid shear stress (FSS).13
In contrast, cancer cells in solid tumors are subjected to
high interstitial ﬂuid pressure caused by the stiff extra-
cellular matrix.59,129 Additionally, certain CTCs gain
the advantage of metastasis via interactions with
different blood cells (neutrophils, macrophages,
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platelets, etc.) whereas solid tumors become aggressive
by beneﬁting from hypoxia or certain tumor-promoting
cells such as tumor-associated macrophages.40,62,84,147
These differences suggest that existing nanomedicines
dependent on the EPR effect for targeted drug delivery
must be tailored to the speciﬁc requirements for the
neutraliza tion of CTCs in circulation (Fig. 1).
In this review,we summarize the interactions ofCTCs
with diﬀerent host cells during their hematogenous
transit and how blocking CTC–host cell interactions
via drug molecules have reduced metastases in
animal models of cancer. Since the majority of these
drugs suffer from fast clearance from circulation,
methods to improve their circulation time through
existing nanotechnologies will be discussed. Particular-
ly, novel biomimetic CTC-targeting nanotechnologies
are highlighted. Finally, potential CTC neutralization
strategies that bridge conventional nanomedicine with
technologies that are being utilized for CTC isolation
and enumeration are discussed.
BIOLOGY OF CIRCULATING TUMOR CELLS
Aberrant Biological Events in CTCs
Solid tumors, at eitherprimaryormetastatic locations,
can be accessed surgically in suﬃcient quantity for diag-
nostic tests and studies involving genomic sequencing,
gene expressionmicroarrays, immunohistology andmass
spectrometry. In contrast, it remains a challenge to study
the biology of rare CTCs in blood with conventional
techniques. Eﬃcient CTC isolation together with single-
FIGURE 1. Two different contexts for the delivery of nanomedicines: solid tumor vs. the blood circulation. In a solid tumor,
nanomedicine migrates to the tumor through leaky tumor-associated vasculature where dysfunctional lymphatic drainage enables
accumulation of nanomedicine in the tumor. In contrast, once cancer cells are shed into the blood circulation to form CTCs, they
are subjected to environmental changes such as shear stress, abundant RBCs and plasma proteins, and interactions with pla-
telets, endothelial cells and other vascular components
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cell RNA-sequencing, exosome sequencing and im-
munoﬂuorescence staining have enabled the discovery of
several intracellular biological events underlying CTC-
mediated metastasis. These events include but are not
limited to: upregulation of Wnt2 in pancreatic cancer-
derived CTCs,155 p53 mutation within CTCs of prostate
cancer,88 activation of TGF-b and BMP signaling in
CTCs from melanoma,89 and EGFR mutation in lung
cancer CTCs.34 More generally, in nearly all epithelial
cancers, a subpopulation of CTCs exist that are charac-
terized by epithelial-to-mesenchymal transition (EMT)
markers.10,12,85,152,156 During EMT, representative ep-
ithelial markers such as EpCAM and E-cadherin are
downregulated, keratin expression pattern is altered, and
mesenchymalmarkers such asN-cadherin, vimentin, and
Snail are upregulated in turn.63,115 Entry to the mes-
enchymal state confers speciﬁc properties to CTCs in-
cluding invasiveness, resistance to anoikis, chemo-
resistance, and cancer stemness.2,36,90,107 Regardless of
changes in signaling pathways and genomic integrity
identiﬁed in CTCs, it remains to be answered whether
these alterations merely mirror tumor progression and
evolution occurring at primary and secondary tumors
where CTCs are being shed. It has been postulated that
subpopulations of metastasis-initiating cells (MICs) and
cancer stem cells (CSCs) contribute to metastases in dis-
tant organs.3,11 It is of clinical signiﬁcance if targeting of
the aberrant signaling pathways could reduce the fre-
quency of MICs and CSCs and thereby lead to better
prognosis.
Selectin-Mediated Hematogenous Metastasis
Selectins (L-, E-, and P-selectin) are integral mem-
brane glycoproteins. They share several structurally
similar domains: an N-terminal C-type lectin domain,
an epidermal growth factor (EGF)-like domain, a
variable number of short consensus repeats (2, 6, and 9
for L-, E-, and P-selectin, respectively), a single-pass
transmembrane domain, and a short intracellular C-
terminal tail.83 L-selectin is constitutively expressed on
the surface of leukocytes whereas E- and P-selectin are
restricted to inﬂamed endothelial cells, and P-selectin
on activated platelets.44 It has been well accepted that
during inﬂammation, the presence of E- and P-selectin
on the endothelium causes the rolling and migration of
neutrophils and monocytes which express selectin li-
gands.123,158
Selectin ligands, however, are not limited to leuko-
cytes and they have been identiﬁed on the surface of
certain cancer cells. Several lines of evidence support
that both E- and P-selectin facilitate the rolling and
adhesion of CTCs in hematogenous metastasis. Ko¨hler
et al. provided the ﬁrst in vivo ﬁnding that E- and
P-selectin are essential for colorectal cancer metastasis.
In their study, E- and P-selectin double knockout mice
had a 84% reduction of lung metastatic nodules by
number compared to wild-type mice after they were
subcutaneously implanted with HT29 colon cancer
cells.68 Lung endothelial cells, however, do not con-
stitutively express E- and P-selectin unless they receive
inﬂammatory signals. It is not clear how selectins
mediated the adhesion of HT29 cells to the lung en-
dothelium. In contrast to the lungs, endothelial cells in
the bone marrow constitutively express E-selectin.49,146
Studies have shown that E-selectin ligands on both
human and mouse prostate cancer (PCa) cells facilitate
bone metastasis in an E-selectin dependent man-
ner.15,86,150 Instead of utilizing E-selectin knockout
mice, these two studies overexpressed a-1,3 fucosyl-
transferases (FTs) in E-selectin ligand (ESL)-negative
human and mouse PCa cell lines based on the ﬁndings
that ESL-positive PCa cells highly express FT3, 6 or
FT7. Consequently, these engineered PCa cells pro-
duced increased incidence of bone metastasis in mice.
The role of speciﬁc selectin ligands in mediating the
hematogenous metastasis of CTCs has been reviewed
extensively elsewhere.41,69,84 This review, however, fo-
cuses on how nanobiotechnology can be utilized to
inhibit the interaction between cancer cells and the
endothelium for the prevention of metastasis.
Given that selectins recognize sialylated fucosylated
glycans on selectin ligands such as sLex, sLex analogs
have been explored as competitive inhibitors for the
binding of CTC selectin ligands to E- and P-selectin.
For instance, a sLex analog, GSC-150, was tested for
its effect on hepatic metastasis of human colon carci-
noma in nude mice. It was found that liver metastases
were signiﬁcantly attenuated when cancer cells were
co-administered with GSC-150.130 In addition to sLex
analogs, compounds that can interfere with the syn-
thesis of sLex represent another class of selectin in-
hibitors. We previously showed that a ﬂuorinated
fucose mimetic (2F-Peracetyl-Fucose) could be used to
reduce E-selectin-dependent bone metastasis in mice
by inhibiting the activity of FT6.86
Contribution of Platelets to CTC-Mediated Metastasis
The involvement of platelets in cancer was ﬁrst re-
ported in the mid-nineteenth century by the French
clinician Armand Trousseau.141 He diagnosed patients
with migratory thrombophlebitis caused by an occult
visceral carcinoma. Mounting evidence has shown that
the interaction of platelets with tumor cells can pro-
mote metastasis through several mechanisms. For in-
stance, interactions with platelets protect CTCs from
immune-mediated clearance,77,102,106 because such ad-
hesion events affect the recognition of CTCs by natural
killer cells. Platelet aggregation can result in the
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grafting of MHC class I ligands onto CTCs, which are
typically absent. The newly acquired ligands prevent
natural killer cells from identifying the CTCs as ‘‘non-
self’’ and spare them from attack.114 Additionally,
activated platelets can induce EMT as well as pro-
survival and pro-metastatic signaling in tumor cells,
which are associated with enhanced invasiveness and
metastatic potential.35,74,75
It has been demonstrated that therapies targeting
the interactions between platelets and CTCs can reduce
the formation of secondary metastases. One approach
to minimizing these interactions has focused on uti-
lizing anti-coagulation agents. Agents such as recom-
binant mouse tissue factor pathway inhibitor (TFPI)
and Cilostazol have been found to reduce the forma-
tion of secondary metastases.8,9,145 Unfortunately, the
use of anticoagulants may also adversely affect the
normal hemostatic function of platelets in the case of
bleeding. A more focused approach aims to block the
signaling between platelets and CTCs. Invasive be-
havior can be induced by transforming growth factor-
b1 (TGF-b1), which is secreted by activated platelets.
Temporary contact with platelets is sufﬁcient to induce
invasive behavior in CTCs through TGF-b1.74 Block-
age of TGF-b1 receptor I (TbR1) kinase activity
through the use of SD-208, a small molecule inhibitor,
was shown to prevent the development of TGF-b in-
duced bone metastases in a melanoma mouse model.100
Thus, blocking platelet-CTC signaling is a potentially
viable targeted therapy to prevent the formation of
additional metastases.
CHALLENGES OF TARGETING CTCS BY
NANOMEDICINE
Although nanomedicine is a very general concept
and represents a broad range of nanoformulations for
existing drugs, it manifests itself largely in targeted
drug delivery and controlled release. The biological
characteristics of CTCs and the physical environment
where they reside may pose certain challenges and
problems when targeted by nanomedicine (Table 1).
Searching for a rare number of CTCs in circulation is
likely analogous to the problem of ﬁnding a needle in
a haystack.5,47 This challenge may be solved by
adopting the strategies utilized for CTC capture and
enrichment. For example, targeting moieties for CTC
isolation, such as anti-EpCAM monoclonal antibody,
can be functionalized onto nanoparticles for the
recognition of CTCs with epithelial origin in the cir-
culation.28
The heterogeneity of CTCs, however, dictates that
there is no universal antigen for comprehensive tar-
geting. CTC phenotypes can be categorized into ep-
ithelial (epithelial+/mesenchymal), complete EMT
(epithelial/mesenchymal+), and intermediate EMT
(epithelial+/mesenchymal+).73,78 It is possible that all
three phenotypes exist in the circulation simultane-
ously and thus targeting CTCs with epithelial features
may become ineffective against those with mes-
enchymal characteristics.161 Moreover, CTCs can also
be divided into CSCs and non-CSCs according to
their tumor-initiating capability, which is not neces-
sarily coupled to the EMT status.149 This raises the
question of whether it is necessary to neutralize all
CTCs in circulation to achieve a net reduction in
metastasis.
CTCs have been detected both as individual cells
and as cellular clusters in blood.24,66 Although rare
in circulation compared to individual CTCs, CTC
clusters show increased invasiveness, are more resis-
tant to anoikis and have a higher likelihood of be-
coming trapped in microvessels, thereby favoring
their survival and extravasation into distant or-
gans.46,163 In a study using breast cancer CTCs, it
TABLE 1. Challenges of targeting CTCs by nanomedicine.
CTC properties Practical consequences Refs.
Rarity of CTCs: a needle in a
haystack problem
Low efficiency of targeting CTCs 5, 47
Heterogeneous subpopulations Mesenchymal CTCs are not recognized by nanomedicine
targeting epithelial cell markers such as EpCAM; Necessity
of killing all CTCs vs. MICs or CSCs in the circulation;
Differential drug resistance among different subpopulations
73,78,149,161
Formation of CTC clusters Increased invasiveness, resistance to anoikis and trapping in
microvessels
1,24,46,66,163
Short circulation time of CTCs Limited exposure time to therapeutics against CTCs in circulation 93,125,135
Shielding of CTCs by platelets Physical barrier to penetration of nanomedicine into CTCs;
pro-metastatic role via induction of EMT, establishment
of early metastatic niches, pro-survival signaling etc.
35,74,75




was been found that CTC clusters display a 23- to
50-fold increase in metastatic potential. Moreover,
high expression of the cell junction protein pla-
koglobin was identiﬁed as responsible for this inter-
cellular adhesion.1 In addition to promoting
invasiveness, it is reasonable that, in large cell ag-
gregates, the cells within the core may be less ac-
cessible to nanomedicine approaches compared to
those at the periphery.
Recently, ex vivo culture of breast cancer CTCs has
enabled individualized testing of drug suscepti-
bility.157 Although such a strategy is mainly utilized
for the treatment of solid tumors, which are the origin
of the CTCs expanded ex vivo, it remains unclear
whether the drugs selected from such screening would
be effective against CTCs in blood compared to the
CTC cell lines expanded in culture medium. In light
of several protective effects associated with the ad-
hesion of platelets to CTCs in blood as discussed in
the ‘‘Contribution of Platelets to CTC-Mediated
Metastasis’’ section, platelet shielding may not only
provide a physical barrier to nanomedicine-mediated
drug delivery to CTCs, but also potentially confer
drug resistance.
The systemic dissemination of CTCs deﬁnes a re-
quirement that nanomedicine vehicles must exist in
the circulation for an extended period of time to
patrol for metastatic CTCs released from solid tu-
mors. When conventional cancer drugs with systemic
cytotoxicity such as doxorubicin and paclitaxel are
utilized for CTC neutralization, they should ideally
be released only after nanocarriers encapsulating the
drugs have been internalized into CTCs to avoid
oﬀ-target eﬀects on normal tissues.136,162 In contrast,
when more cancer-speciﬁc therapeutics such as
monoclonal antibodies and tumor necrosis factor-re-
lated apoptosis-inducing ligand (TRAIL) are applied
to target CTCs, such systemic toxicity may be less of
a concern.70,126,143 In addition to their systemic na-
ture, CTCs are reported to have a relatively short
half-life (<24 h) in circulation.93,125,135 This provides
a narrow time window for efﬁcient killing of CTCs
via nanomedicine approaches. A rational solution to
this challenge is to design nanocarriers with extended
circulation times. Recently, our group demonstrated
for the ﬁrst time that leukocytes coated with na-
noscale TRAIL-liposomes were able to efﬁciently
neutralize CTCs in an experimental mouse model of
metastasis. This approach utilizes the long circulation
time of leukocytes to deliver an apoptosis signal to
cancer cells with minimal side effects on normal cells
such as leukocytes and endothelium.95 An alternative
strategy, however, is to deliver drugs that inhibit
intravasation of cancer cells via enhanced tumor cell–
matrix interactions.164
POTENTIAL PARADIGMS OF CONVENTIONAL
NANOMEDICINE IN CTC NEUTRALIZATION
Despite the promise of utilizing synthetic com-
pounds for blocking selectin-mediated CTC metastasis
or inhibitors for blocking platelet–CTC interactions
and signaling, these compounds are likely to be cleared
from the body within a short time period via renal
ﬁltration due to their relatively low molecular weight
(LMW).87 Therefore, frequent administration of these
molecules is necessary and may become prohibitively
expensive for clinical implementation. Nevertheless,
the paradigms that have been exploited for nanopar-
ticles and nanoformulations over the past few decades
are potentially applicable to extend the circulation time
of these LMW compounds. To date, two nanoformu-
lations for treating solid tumors have been approved
for clinical use, speciﬁcally liposomal doxorubicin
(Doxil) and protein-bound paclitaxel (Abraxane).37
One major obstacle to using nanoparticles in vivo is
rapid clearance by the mononuclear phagocyte system
(MPS). The main strategy for extending the circulation
time of nanoparticles is by grafting uncharged hy-
drophilic polymers onto the surface of particles to
create so-called ‘‘stealth’’ particles, with the most
commonly used polymer being polyethylene glycol
(PEG).110,116,127 By encapsulating sLex analogs or fu-
cosyltransferase inhibitors into nanoparticles with
PEG-coated surfaces, this is likely to achieve both
controlled drug release and extended circulation time.
In addition to the intervention of selectin-mediated
adhesion of CTCs to endothelium via ESL inhibitor-
encapsulated nanoparticles, a coexisting or alternative
adhesion event mediated by ICAM-1 (expressed on
vascular endothelium) and MUC1 (expressed on some
CTCs) has been shown as a potential target for the
prevention of metastasis.117,121 The Decuzzi lab re-
cently demonstrated that long circulating lipid–poly-
mer nanoparticles encapsulating curcumin were able to
substantially reduce the adhesion of highly metastatic
human breast cancer cells MDA-MB-231 to TNF-a-
treated HUVEC cells in an ICAM-1- and MUC1-de-
pendent manner.111 It remains to be determined,
however, whether such curcumin-encapsulated
nanoparticles would be effective in mouse models with
experimental and/or spontaneous metastases.
Alternatively, sLex or synthetic sLex analogs can be
functionalized onto the surface of nanoparticles for
targeting tumor-associated endothelium. For instance,
sLex-conjugated liposomes loaded with cisplatin have
been shown to accumulate on an E-selectin-expressing
endothelium in the vicinity of tumor cells. It was found
that sLex-conjugated liposomes enabled sixfold higher
cisplatin accumulation than non-conjugated liposomes
in tumors.45 Although this nanoformulation was in-
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tended to target solid tumors as opposed to CTCs, an
additional beneﬁt may have been to help neutralize
CTCs that reseed into solid tumors.65 Bone-metastatic
prostate cancer (PCa) cells bearing ESLs are known to
attach more avidly to bone marrow (BM) endothelial
cells which constitutively express E-selectin.14,86
Therefore, sLex-conjugated nanoparticles encapsulat-
ing cancer therapeutics can potentially deliver con-
ventional cancer drugs to the BM niche of CTCs for
the prevention and treatment of BM metastasis in
prostate cancer.
ADVANCED NANOTECHNOLOGIES IN CTC
TARGETING
Eﬀect of Nanoparticle Morphology on Their Fate in
Blood Circulation
Many nanoparticle designs have been proposed for
cancer therapy and diagnosis, with varied biodistribu-
tion in the blood circulation depending on their ad-
ministration route, particle size, composition, and
surface charge.18 In general, polymeric nanoparticles
less than 10 nm in diameter may be easily cleared by the
kidneys as blood carries them through the renal system,
and particles greater than 100 nm may be easily cleared
by phagocytic uptake and hepatic ﬁltration.4 For the
targeting of CTCs that extravasate from the vessel wall
of the microvasculature, nanoparticles that exhibit the
capability to adhere to the vascular wall may be more
effective at delivering therapeutic cargo to CTCs.122
Gentile et al.43 have shown that for spherical particles,
large particles will have better margination compared
to small particles that are less than 200 nm in diameter.
Margination is a biorheological process in which semi-
rigid cells and particles are displaced toward the vessel
wall in circulation, providing more opportunities for
interactions with the endothelium43 such as CTC in-
travasation and extravasation and blockade of these
processes. The shape of nanoparticles is an important
factor in determining their behavior in the blood cir-
culation, where the adhesive interactions between par-
ticles and cells have to counteract the hemodynamic
forces exerted by the ﬂowing blood.29 These two
counteracting forces will affect the particles’ targeting
and attachment abilities within the microvasculature.
Various shapes of nanoparticles, such as spherical,
hemispherical, discoidal, cylindrical, conical, vase- and
rod-shaped, have all been manufactured with emerging
nanofabrication technologies and have demonstrated
differential behaviors in ﬂow.22,30
In ﬂowing blood, a spherical morphology is suited
for rotational motion,58 which is important for
leukocytes that roll on and interact with the endothe-
lium. In contrast to symmetric spherical particles (in-
cluding cells), non-spherical particles may align or
tumble under ﬂow, with surprising transport proper-
ties. For example, red blood cells (RBCs), having a
ﬂexible biconcave disc shape with an average diameter
of 8 lm,108 routinely pass through the reticular mesh-
work ﬁltering units in the sinusoidal spleen in which
the cell slit size rarely exceeds 200–500 nm in width,
whereas spherical nanoparticles must be less than
200 nm in diameter to do so.22,99 In contrast to rigid
spheres, biconcave discs are found to deform to other
shapes such as parachute and slipper-like morpholo-
gies in response to changes in local ﬂow velocity and
shear stress, yet they retain the ability to recover their
discoidal shape at reduced velocity.108 Shape ﬂexibility
and deformability allow RBCs to pass through vessels
of different dimensions and narrow constrictions,
making them an excellent vehicle for traveling in
blood. Another important type of blood cell, platelets,
normally exhibiting an oblate spheroidal shape, have
been shown to assume different morphologies in vitro
after prolonged exposure to adhesive surfaces.58 Acti-
vated platelets resemble spheres with a rough surface.
The activated platelet shape greatly inﬂuences platelet
collisions, including the frequency, contact time and
available area of collision, as well as the magnitude of
shear and normal forces acting on the cells.98
Inspired by nature’s adaptation of non-spherical
particles for unique transport properties and cellular
interactions in ﬂowing blood, synthetic particles of
various shapes have been developed and evaluated for
drug delivery in recent years.29 For instance, Decuzzi
et al.30 injected silicon-based particles of quasi-hemi-
spherical, cylindrical, and discoidal shapes into tumor-
bearing mice and observed different distribution pro-
ﬁles among these particles. They further showed that
discoidal particles can maximize accumulation in tar-
get organs while reducing sequestration by the liver.
Geng et al.42 prepared ﬁlomicelles, which are ﬂexible
ﬁlamentous vehicles that have been shown to effec-
tively and efﬁciently deliver the anticancer drug pacli-
taxel to tumors in mice,20 that persist in circulation 10
times longer than their spherical counterpart. Gandra
et al.38 modiﬁed a ﬁlamentous bacteriophage and
demonstrated its potential use as a biological nanowire
to convey cargos of cancer-targeting peptides and
photosensitizing agents. Bruckman et al.19 prepared
viral nanoparticles in the forms of rods and spheres,
and observed that the nanorods circulated longer in
the bloodstream of mice and were cleared from tissues
more slowly compared to nanospheres. Theoretical
and experimental calculations further conﬁrmed the
distinctive diffusion proﬁles of these two shapes in the
tumor microenvironment.82 Carbon nanotubes
(CNTs) have attracted much attention in drug delivery
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research due to their long circulation time and the ef-
ﬁcient methodologies for chemical modiﬁcation.17 For
example, Yinghuai et al.151 constructed water-soluble
functionalized CNTs as delivery vehicles of cancer
therapeutics—BNCT agents—which were found to be
concentrated in tumor cells in mice.
These bio-inspired approaches exploiting non-
spherical particles for tumor homing are directly ap-
plicable for the targeting of CTCs in the bloodstream.
Elongated, rod-shaped and ﬁlamentous materials
possess distinctive transport properties compared to
spheres due to their enhanced ﬂexibility and perme-
ability. They also show improved margination toward
the vessel wall,79,82 and are thus potentially more ef-
fective at accessing diseased vessels and CTCs.82
Moreover, the extended circulation lifetime of these
particles can increase their probability of interaction
with CTCs. Although non-spherical nanoformulations
are promising anticancer drug delivery vehicles, they
represent an emerging ﬁeld that requires more exten-
sive evaluations, including focus on mechanical prop-
erties, polydispersity, and stability of the carriers. In
addition, other design parameters can have signiﬁcant
effects on vascular transport properties as well. For
example, size and density are important in particle
design. A ﬁne balance among these three fac-
tors—shape, size and density—may allow for the de-
sign of particles with enhanced vascular interactions80
that are able to mimic biomolecules and cells, sensing
and interacting with endothelial cells and CTCs in the
blood circulation.
Biomimetic Strategies for Drug Delivery to CTCs
Red blood cells (RBCs), or erythrocytes, have been
exploited as drug delivery vehicles since Inler et al.54
ﬁrst created enzyme-loaded RBC ghosts in the early
1970s.104 Their work continues to inspire the design
and engineering of biomimetic delivery systems today.
Drug delivery vehicles derived from natural RBCs can
be divided into four major classes:50 (1) carrier RBCs,
which are natural RBC ghosts carrying therapeutic
cargos; (2) synthetic RBC-mimicking particles, which
are made of polymers that aim to simulate the me-
chanical and chemical properties of RBCs; (3) RBC
membrane-derived liposomes, which are synthesized
from native RBC membranes; and (4) RBC-membrane
camouﬂaged nanoparticles (RBC-NPs), which are
nanoparticles coated with native RBC membranes.
Although RBC derivatives have not been exten-
sively evaluated in the context of CTCs, their unique
biomimetic features suggest they are an excellent type
of delivery vehicle for drugs that are intended to act in
the bloodstream,104 and exhibit the potential to effec-
tively target CTCs. Both RBCs and CTCs reside in the
circulatory system, and can travel to different organs
through blood vessels. Therefore, if bioengineered
RBCs are capable of recognizing and eliminating
CTCs in the vasculature before CTCs are able to ex-
travasate, they could prevent cancer cells from
colonizing secondary organs and reduce metastasis. In
addition, human erythrocytes have a life span of 100–
120 days,104 a circulation time much longer than that
of nanoparticle drug carriers at present. Many types of
synthetic nanoparticles sub-100 nm in diameter have a
circulation half-life on the scale of hours, even after
PEGylation.60 The longer blood circulation time of
RBC derivatives enhances drug retention in the body
and allows for sustained drug release,51 as well as in-
creasing the vehicles’ interactions with CTCs.
Another property that makes RBC derivatives an
excellent tool for targeting CTCs is their superior
biocompatibility. The biocompatibility of nanoparti-
cles is dictated by particle size, surface charge, hy-
drophobicity-hydrophilicity, as well as the steric eﬀects
of their outer coating.166 Many polymers used for
nanoparticle stealth coating, such as PEG, create a
hydrophilic shell on the particle surface, thus shielding
the nanoparticles from immune recognition and de-
creasing their rate of elimination.55 In the early 2000s,
however, different groups reported a phenomenon
called ‘‘accelerated blood clearance’’,26 in which re-
peated injections of PEGylated liposomes resulted in
immune rejection in animal studies.26,55–57 This phe-
nomenon raised concerns in the repeated administra-
tion of sterically stabilized nanoparticles for drug
delivery. In contrast to PEGylation, which provides
nanoparticles with an outer shell that attenuates im-
mune recognition, RBC derivatives adopt a different
mechanism by disguising as the ‘‘self’’, which can po-
tentially be more compatible with the immune system
and avoid accelerated blood clearance. Residing in the
same environment as macrophages and lymphocytes,
RBCs evade the immune system by displaying self-
antigens on their outer membrane.50,64,109 RBC
derivatives that incorporate self-antigens, such as
CD47,48 or a complete RBC membrane,39,50,51 have
shown reduced immunogenicity compared to naked
particles. For instance, Gao et al.106 demonstrated a
fourfold reduction in the uptake of gold nanoparticles
(AuNP) coated with RBC membrane by macrophages
in vitro.
Early studies have shown enhanced therapeutic ef-
ﬁcacy and reduced immunogenicity in animal cancer
models treated with erythrocyte-encapsulated antitumor
drugs. In a study by Zocchi et al.,165 murine RBCs
were subjected to hypotonic dialysis followed by dox-
orubicin encapsulation during membrane resealing.
Compared to the non-encapsulated drug, mice treated
with erythrocyte-encapsulated doxorubicin showed
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signiﬁcant inhibition of metastatic growth in liver and
lung at a much lower dosage. Doxorubicin encapsu-
lated in RBCs was also administered to dogs with
lymphosarcoma.91 This treatment achieved sustained
drug release and induced complete and partial remis-
sions of lymphosarcoma in dogs. Skorokhod et al.133
administered doxorubicin-loaded erythrocytes to 15
lymphoma patients and reported improved pharma-
cokinetics compared to those of free doxorubicin, as
well as good tolerance in cancer patients. The same
research group has also studied the pharmacokinetics
of daunorubicin-loaded erythrocytes in patients with
acute leukemia132 and similar ﬁndings were reported,
thus demonstrating the promising clinical applications
of RBC delivery vehicles in treating blood cancers.
Another drug used to treat acute leukemia, L-as-
paraginase, is one of the most widely studied enzymes
for RBC encapsulation.94 Different groups have de-
veloped various methods for preparing asparaginase-
loaded RBCs, which have been evaluated for their
pharmacokinetics and antitumor activities in mice,7,71
dogs,31 monkeys139 and humans.72 These studies have
demonstrated the advantages of using RBC derivatives
for targeting CTCs in vivo.
To date, RBC derivatives have not been reported in
the literature for targeting CTCs that are not of blood
cancer origin. Nevertheless, studies involving leukemia
or lymphoma animal models and human patients have
corroborated the potential use of RBC carriers in tar-
geting non-blood CTCs. Despite the attractive features
of erythrocyte derivatives in targeted drug delivery,
there are still many clinical challenges. Unlike animals,
humans havemany diﬀerent blood groups. Tomake the
technology more versatile for patients, the removal of
immunogenic antigens is essential during drug synthe-
sis.51 In addition, because of their biological origin,RBC
derivatives are difﬁcult and expensive to store. They also
present great variability, which makes standardization
and scale-up challenging.94 At present, there is no
known receptor or ligand on the native RBCmembrane
that would allow RBC vehicles to interact with CTCs in
the circulation. A potential solution is to create RBC
derivatives carrying antibodies that would speciﬁcally
recognize CTC surface antigens such as EpCAM, which
is present in many types of CTCs. EpCAM expression
on CTCs is also found to correlate with metastatic
cancer prognosis.120,124 Conjugation of various mole-
cules, including antibodies, to RBC membranes can be
accomplished through a biotin-avidin linkage.50,103
In contrast to RBC biomimetic platforms that pri-
marily seek to improve drug circulation time and
biocompatibility, nanoparticles that mimic behaviors
of platelets may not only extend the half-life of
particles in blood but also bind CTCs with mechanisms
similar to natural platelets. A platelet-mimetic ap-
proach for metastasis-targeted nanomedicine has been
recently developed. In a study from the Gupta group,97
highly metastatic human breast cancer cells MDA-
MB-231 were examined for surface expression of pla-
telet-interactive receptors, which were then compared
to a weakly metastatic human breast cancer cell line,
MCF-7. Interestingly, certain platelet-interactive re-
ceptors were found to be signiﬁcantly overexpressed on
the surface of MDA-MB-231 cells such as GPIIb-IIIa-
like receptors (which can bind to platelets mediated by
ﬁbrinogen), P-selectin (which can bind to platelets
mediated by sialoprotein ligands), GPIa-IIa-like re-
ceptors (which can bind to platelets mediated by col-
lagen-like molecules), E-selectin (which can bind to
sialyl Lewis moieties), integrin aVb3 (which can bind to
ﬁbronectin, vitronectin, etc.), and GPIba-like proteins
(which can bind to von Willebrand factor). In contrast,
these receptors were weakly expressed in MCF-7 cells.
More importantly, MDA-MB-231 cells showed sig-
niﬁcantly enhanced binding interactions with active
platelets compared to MCF-7 cells. In light of these
differences, two speciﬁc receptors were selected
(GPIIb-IIIa-like integrin and P-selectin), and their
corresponding ligands were engineered onto the sur-
face of liposomes to enable platelet-mimetic binding to
the cancer cells under physiological ﬂow conditions.
Nevertheless, it remains to be answered whether such a
platelet-mimetic approach could target real CTCs in a
patient’s blood. To address this question, both a mouse
metastatic cancer model and patient-derived blood
containing CTCs will need to be tested. In addition,
the in vivo biodistribution and circulation time of such
nanomedicines must be measured. Despite the uncer-
tainties that remain to be addressed, this represents the




Enumeration of CTCs in the peripheral blood of
cancer patients has shown promise for the diagnosis and
monitoring of cancer progression, and it serves as an
alternative to conventional imaging methods.61,96,154
CTCs of epithelial origin are deﬁned as being positive for
epithelial cell adhesion molecule (EpCAM+) and cy-
tokeratin 8, 18, or 19 (CK+), and negative for CD45
(CD45).6 Therefore, approaches for isolating such
CTCs are largely based on the positive selection for ep-
ithelial markers.25,138 The existence of EpCAM-negative
CTCs (i.e., CTCs with EMT signature), necessitates ap-
proaches such as negative depletion to select for CD45
cells.33 Alternatively, label-independent enrichment
methods that are based on size and/or density differences
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between cancer cells and blood cells have also been de-
veloped for CTC enrichment.112,142 In addition to cell
heterogeneity, the rarity of CTCs in blood relative to
white blood cells has made their detection and isolation
even more challenging.5,10,47 To solve this problem,
nanomaterials have been developed to enable high-den-
sity coatings of different capture molecules such as an-
tibodies for improved sensitivity of CTC detection.148
Recently, silicon nanopillars,144 quartz nanowires81 and
TiO2 nanoﬁbers
159 have been used to trap CTCs, with
enhanced capture efﬁciency due to the higher aspect ratio
of the nanomaterials. Moreover, when such nanomate-
rial-based platforms have been integrated with ﬂow-
based systems such as microﬂuidic devices, a signiﬁcant
increase in capture yield is observed via continuous ﬂow
of patient blood through the devices.32,105,153
In contrast to the rapid development ofCTC isolation
technologies, few studies have been performed to enable
drug delivery through CTC enrichment devices. It is
conceivable that anti-EpCAM-conjugated nanoparticles
loaded with cancer drugs could be utilized for targeting
CTCs of epithelial state in blood. Moreover, by com-
bining high capture eﬃciency of 3D nanotopographic
features such as silicon nanowires with enhanced drug
encapsulation for nanoporous materials, novel
nanomedicines can possibly target a subpopulation of
CTCs with CSC properties or multi-drug resis-
tance.67,113,128 In addition, since mouse models and
clinical observations have provided evidence that CTC
count correlates with disease progression in cancer pa-
tients,28,65,154,160 it is intriguing that an implanted shunt
system with similar nanostructure and surface func-
tionalization could be utilized to ﬁlter out rare CTCs
from the blood circulation. As a proof-of-concept, our
group invented a biomimetic approach to capture and
kill CTCs in vitro. In this system, a microﬂuidic device
was functionalized with E-selectin, which interacts with
CTCs during extravasation through the endothelium.
Additionally, the surface was coated with a tumor-
speciﬁc cytokine, tumor necrosis factor-related apopto-
sis-inducing ligand (TRAIL), for inducing apoptosis
when CTCs were captured from the ﬂow.118,119 More
recently, the device was further functionalized with
naturally occurring nontoxic halloysite nanotubes for
the enhanced capture of CTCs.52,53 Nevertheless, several
issues need to be addressed to demonstrate the efﬁcacy of
this approach in vivo. First, the device must be com-
patible with the body. As E-selectin and TRAIL are ex-
pressed in host cells, it is unlikely that they will induce an
immune response. It requires, however, further ex-
amination on whether the material that comprises the
device and additional nanostructured surface would
cause any side effects when interfacing with blood.131
Secondly, it is necessary to test the isolation efﬁciency of
CTCs in the presence of abundant plasma proteins in the
blood. It has been found that owing to high surface free
energy, certain nanomaterials adsorb biomolecules upon
contact with biological ﬂuids. In particular, plasma
proteins may bind to the nanostructured surface to form
a biological coating, known as the protein corona.101,137
This corona may affect the interaction of the device with
the host system.134 Lastly, it is crucial to evaluate when
the device surface becomes saturated with CTCs and
requires replacement. Nevertheless, such biomimetic
approaches for the delivery of apoptotic signals repre-
sents an intriguingproofof concept for future integration
of CTC isolation technologies with nanomedicines.
CONCLUSION
In the past decade, the presence of CTCs has been
utilized as an indicator of poor prognosis in several
carcinomas. The diﬃculty of identifying these rare cells
in the blood has driven the development of numerous
devices for the isolation and characterization of CTCs in
clinical settings. It is not until recently, however, that the
presence of metastasis-initiating cells (MICs) among
CTCs has been experimentally demonstrated. There-
fore, neutralizing MICs or CTCs in the blood may rep-
resent a new paradigm for the intervention ofmetastases
in distant organs. In contrast to conventional
nanomedicines, which extend the half life of
chemotherapeutics in the blood, novel approaches that
are inspired by the context of CTCs in circulation have
led to a variety of biomimetic nanoparticle or nanofor-
mulation platforms. Integration of nanotechnologies
with a deeper understanding of diverse CTC–host cell
interactions may oﬀer exciting and promising directions
for novel therapeutic interventions in the future.
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